A citation-based method for searching scientific literature

Jennifer A Crozier, Pooja P Advani, Betsy LaPlant, Timothy Hobday, Anthony J Jaslowski, Alvaro Moreno-Aspitia, Edith A Perez. Clin Breast Cancer 2016
Times Cited: 30







List of co-cited articles
319 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
José Baselga, Patricia Gómez, Richard Greil, Sofia Braga, Miguel A Climent, Andrew M Wardley, Bella Kaufman, Salomon M Stemmer, António Pêgo, Arlene Chan,[...]. J Clin Oncol 2013
252
56

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.
Lisa A Carey, Hope S Rugo, P Kelly Marcom, Erica L Mayer, Francisco J Esteva, Cynthia X Ma, Minetta C Liu, Anna Maria Storniolo, Mothaffar F Rimawi, Andres Forero-Torres,[...]. J Clin Oncol 2012
353
53

Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
J M Nabholtz, N Chalabi, N Radosevic-Robin, M M Dauplat, M A Mouret-Reynier, I Van Praagh, V Servent, J P Jacquin, K E Benmammar, S Kullab,[...]. Int J Cancer 2016
40
46

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011
46


Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer.
Olivier Trédan, Mario Campone, Jacek Jassem, Rostislav Vyzula, Bruno Coudert, Carmen Pacilio, Jana Prausova, Anne-Claire Hardy-Bessard, Ana Arance, Pralay Mukhopadhyay,[...]. Clin Breast Cancer 2015
40
40

High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.
Heae Surng Park, Min Hye Jang, Eun Joo Kim, Hyun Jeong Kim, Hee Jin Lee, Yu Jung Kim, Jee Hyun Kim, Eunyoung Kang, Sung-Won Kim, In Ah Kim,[...]. Mod Pathol 2014
164
33

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
Maura N Dickler, Melody A Cobleigh, Kathy D Miller, Pamela M Klein, Eric P Winer. Breast Cancer Res Treat 2009
100
26


A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.
Martin Schuler, Ahmad Awada, Philipp Harter, Jean Luc Canon, Kurt Possinger, Marcus Schmidt, Jacques De Grève, Patrick Neven, Luc Dirix, Walter Jonat,[...]. Breast Cancer Res Treat 2012
52
23

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer.
Gunter von Minckwitz, Walter Jonat, Peter Fasching, Andreas du Bois, Ulrich Kleeberg, Hans-Joachim Lück, Erika Kettner, Jörn Hilfrich, Wolfgang Eiermann, Julie Torode,[...]. Breast Cancer Res Treat 2005
127
23

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
23

A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Katsuya Nakai, Mien-Chie Hung, Hirohito Yamaguchi. Am J Cancer Res 2016
179
23

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Ingrid A Mayer, Linda T Vahdat, Sara M Tolaney, Steven J Isakoff, Jennifer R Diamond, Joyce O'Shaughnessy, Rebecca L Moroose, Alessandro D Santin, Vandana G Abramson,[...]. N Engl J Med 2019
350
23

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial.
Mogens Bernsdorf, Christian Ingvar, Leif Jörgensen, Malgorzata K Tuxen, Erik H Jakobsen, Anna Saetersdal, Marie Louise Kimper-Karl, Niels Kroman, Eva Balslev, Bent Ejlertsen. Breast Cancer Res Treat 2011
55
20

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.
José Baselga, Joan Albanell, Amparo Ruiz, Ana Lluch, Pere Gascón, Vicente Guillém, Sonia González, Silvia Sauleda, Irene Marimón, Josep M Tabernero,[...]. J Clin Oncol 2005
276
20

Trastuzumab emtansine for HER2-positive advanced breast cancer.
Sunil Verma, David Miles, Luca Gianni, Ian E Krop, Manfred Welslau, José Baselga, Mark Pegram, Do-Youn Oh, Véronique Diéras, Ellie Guardino,[...]. N Engl J Med 2012
20

Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
Denise A Yardley, Patrick J Ward, Brooke R Daniel, Janice F Eakle, Ruth E Lamar, Cassie M Lane, John D Hainsworth. Clin Breast Cancer 2016
24
25

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.
Mothaffar F Rimawi, Priya B Shetty, Heidi L Weiss, Rachel Schiff, C Kent Osborne, Gary C Chamness, Richard M Elledge. Cancer 2010
146
16

Untangling the ErbB signalling network.
Y Yarden, M X Sliwkowski. Nat Rev Mol Cell Biol 2001
16

Triple-negative breast cancer.
William D Foulkes, Ian E Smith, Jorge S Reis-Filho. N Engl J Med 2010
16

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
16

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Rita Nanda, Laura Q M Chow, E Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, Gursel Aktan, Jonathan D Cheng,[...]. J Clin Oncol 2016
897
16

Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway.
Hui-Wen Lo, Sheng-Chieh Hsu, Mohamed Ali-Seyed, Mehmet Gunduz, Weiya Xia, Yongkun Wei, Geoffrey Bartholomeusz, Jin-Yuan Shih, Mien-Chie Hung. Cancer Cell 2005
389
16

PD-L1 expression in triple-negative breast cancer.
Elizabeth A Mittendorf, Anne V Philips, Funda Meric-Bernstam, Na Qiao, Yun Wu, Susan Harrington, Xiaoping Su, Ying Wang, Ana M Gonzalez-Angulo, Argun Akcakanat,[...]. Cancer Immunol Res 2014
732
16

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
Abderrahim El Guerrab, Mahchid Bamdad, Fabrice Kwiatkowski, Yves-Jean Bignon, Frédérique Penault-Llorca, Corinne Aubel. Oncotarget 2016
55
16

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Sung-Bae Kim, Rebecca Dent, Seock-Ah Im, Marc Espié, Sibel Blau, Antoinette R Tan, Steven J Isakoff, Mafalda Oliveira, Cristina Saura, Matthew J Wongchenko,[...]. Lancet Oncol 2017
274
16

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Nicholas J Robert, Véronique Diéras, John Glaspy, Adam M Brufsky, Igor Bondarenko, Oleg N Lipatov, Edith A Perez, Denise A Yardley, Stephen Y T Chan, Xian Zhou,[...]. J Clin Oncol 2011
735
16

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
Torsten O Nielsen, Forrest D Hsu, Kristin Jensen, Maggie Cheang, Gamze Karaca, Zhiyuan Hu, Tina Hernandez-Boussard, Chad Livasy, Dave Cowan, Lynn Dressler,[...]. Clin Cancer Res 2004
13

Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.
Giuseppe Viale, Nicole Rotmensz, Patrick Maisonneuve, Luca Bottiglieri, Emilia Montagna, Alberto Luini, Paolo Veronesi, Mattia Intra, Rosalba Torrisi, Anna Cardillo,[...]. Breast Cancer Res Treat 2009
147
13

Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.
V Martin, F Botta, E Zanellato, F Molinari, S Crippa, L Mazzucchelli, M Frattini. Histol Histopathol 2012
50
13

Triple negative tumours: a critical review.
J S Reis-Filho, A N J Tutt. Histopathology 2008
656
13

The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
Sohrab P Shah, Andrew Roth, Rodrigo Goya, Arusha Oloumi, Gavin Ha, Yongjun Zhao, Gulisa Turashvili, Jiarui Ding, Kane Tse, Gholamreza Haffari,[...]. Nature 2012
13

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Lisa A Carey, E Claire Dees, Lynda Sawyer, Lisa Gatti, Dominic T Moore, Frances Collichio, David W Ollila, Carolyn I Sartor, Mark L Graham, Charles M Perou. Clin Cancer Res 2007
13

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, Suet-Feung Chin, Gulisa Turashvili, Oscar M Rueda, Mark J Dunning, Doug Speed, Andy G Lynch, Shamith Samarajiwa, Yinyin Yuan,[...]. Nature 2012
13

A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.
S Cowherd, L D Miller, S A Melin, S Akman, S Isom, J Cole, A Pullikuth, J A Lawrence. Cancer Biol Ther 2015
21
19

Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
Wei-Chien Huang, Yun-Ju Chen, Long-Yuan Li, Ya-Ling Wei, Sheng-Chieh Hsu, Shing-Ling Tsai, Pei-Chun Chiu, Wei-Pang Huang, Ying-Nai Wang, Chung-Hsuan Chen,[...]. J Biol Chem 2011
126
13

Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
Toni M Brand, Mari Iida, Emily F Dunn, Neha Luthar, Kellie T Kostopoulos, Kelsey L Corrigan, Matthew J Wleklinski, David Yang, Kari B Wisinski, Ravi Salgia,[...]. Mol Cancer Ther 2014
41
13

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
William M Sikov, Donald A Berry, Charles M Perou, Baljit Singh, Constance T Cirrincione, Sara M Tolaney, Charles S Kuzma, Timothy J Pluard, George Somlo, Elisa R Port,[...]. J Clin Oncol 2015
569
13

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
M Martín, A Chan, L Dirix, J O'Shaughnessy, R Hegg, A Manikhas, M Shtivelband, P Krivorotko, N Batista López, M Campone,[...]. Ann Oncol 2017
105
13

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Matthew D Burstein, Anna Tsimelzon, Graham M Poage, Kyle R Covington, Alejandro Contreras, Suzanne A W Fuqua, Michelle I Savage, C Kent Osborne, Susan G Hilsenbeck, Jenny C Chang,[...]. Clin Cancer Res 2015
691
13

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
13

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Brian D Lehmann, Bojana Jovanović, Xi Chen, Monica V Estrada, Kimberly N Johnson, Yu Shyr, Harold L Moses, Melinda E Sanders, Jennifer A Pietenpol. PLoS One 2016
611
13

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
Denise A Yardley, Robert Weaver, Michelle E Melisko, Mansoor N Saleh, Francis P Arena, Andres Forero, Tessa Cigler, Alison Stopeck, Dennis Citrin, Ira Oliff,[...]. J Clin Oncol 2015
114
13

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
Johanna Bendell, Mansoor Saleh, April A N Rose, Peter M Siegel, Lowell Hart, Surendra Sirpal, Suzanne Jones, Jennifer Green, Elizabeth Crowley, Ronit Simantov,[...]. J Clin Oncol 2014
74
13

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
David Cameron, Julia Brown, Rebecca Dent, Christian Jackisch, John Mackey, Xavier Pivot, Guenther G Steger, Thomas M Suter, Masakazu Toi, Mahesh Parmar,[...]. Lancet Oncol 2013
295
13

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
13

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Shanu Modi, Cristina Saura, Toshinari Yamashita, Yeon Hee Park, Sung-Bae Kim, Kenji Tamura, Fabrice Andre, Hiroji Iwata, Yoshinori Ito, Junji Tsurutani,[...]. N Engl J Med 2020
621
13

Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
Somaira Nowsheen, Tiffiny Cooper, Jennifer A Stanley, Eddy S Yang. PLoS One 2012
80
10

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M van de Rijn, S S Jeffrey,[...]. Proc Natl Acad Sci U S A 2001
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.